We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Carbapenem-Resistant K. Pneumoniae Driven by Nosocomial Spread

By LabMedica International staff writers
Posted on 15 Aug 2019
Print article
Image: A scanning electron micrograph of two rod-shaped bacteria called Klebsiella pneumoniae that are resistant to treatment with the “last resort” antibiotic drug called carbapenem. In this image, the mustard-colored bacteria are interacting with the green-colored human white blood cells (Photo courtesy of National Institute of Allergy and Infectious Diseases).
Image: A scanning electron micrograph of two rod-shaped bacteria called Klebsiella pneumoniae that are resistant to treatment with the “last resort” antibiotic drug called carbapenem. In this image, the mustard-colored bacteria are interacting with the green-colored human white blood cells (Photo courtesy of National Institute of Allergy and Infectious Diseases).
Public health interventions to control the current epidemic of carbapenem-resistant Klebsiella pneumoniae rely on a comprehensive understanding of its emergence and spread over a wide range of geographical scales.

The number of deaths attributed to carbapenem-resistant K. pneumoniae is on the rise in Europe. In 2007, about 341 deaths there were caused by the bacterium, but in 2015, nearly 2,100 deaths were. In a recent study, hospitals are thought to be a central link in the spread of drug-resistant K. pneumoniae in Europe.

A team of infectious disease specialists led by the University of Freiburg (Freiburg, Germany) collected more than 1,700 bacterial samples from 250 hospitals in 32 countries. Their phylogenetic analysis uncovered four clonal lineages of carbapenem-resistant K. pneumoniae and found that hospitals are a transmission hot spot, which indicates better infection control in hospitals is needed. The hospital laboratories across Europe were asked to submit their first 10 consecutive isolates of either K. pneumoniae or Escherichia coli that were not susceptible to carbapenem alongside isolates from the same species that were susceptible to carbapenem for analysis.

The team reported that overall, 55% of the isolates submitted were thought to be non-susceptible to carbapenem and 455 were thought to be susceptible, and 96% of the isolates belonged to K. pneumoniae sensu stricto. They examined the isolates' genomes for known β-lactam resistance factors, and most of the isolates, 684 of them, carried one or more carbapenemase genes like blaKPC-like and blaOXA-48-like, among others. Most of these carbapenemase gene-containing strains, further, belonged to four K. pneumoniae lineages making up sequence types 11, 15, 101 and ST258/512, and their derivatives.

The investigators measured the genetic relatedness of their samples, and found that their genetically nearest neighbor was from the same hospital for 159 of the 311 isolates carrying the blaKPC-like gene, for 125 of the 248 isolates carrying the blaOXA-48-like gene, for 43 of 79 of those with the blaNDM-like gene, and for 42 of 56 carrying the blaVIM-like gene. This, they said, is indicative of frequent hospital transmissions.

Hajo Grundmann, PhD, a professor and co-senior author of the study, said, “We are optimistic that with good hospital hygiene, which includes early identification and isolation of patients carrying these bacteria, we can not only delay the spread of these pathogens, but also successfully control them. This study emphasizes the importance of infection control and ongoing genomic surveillance of antibiotic-resistant bacteria to ensure we detect new resistant strains early and act to combat the spread of antibiotic resistance.” The study was published on July 29, 2019, in the journal Nature Microbiology.

Related Links:
University of Freiburg

Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
TORCH Infections Test
TORCH Panel
New
Auto Clinical Chemistry Analyzer
cobas c 703

Print article

Channels

Molecular Diagnostics

view channel
Image: The study investigated D-dimer testing in patients who are at higher risk of pulmonary embolism (Photo courtesy of Adobe Stock)

D-Dimer Testing Can Identify Patients at Higher Risk of Pulmonary Embolism

Pulmonary embolism (PE) is a commonly suspected condition in emergency departments (EDs) and can be life-threatening if not diagnosed correctly. Achieving an accurate diagnosis is vital for providing effective... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more
Sekisui Diagnostics UK Ltd.